{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "BOLD",
  "name": "Boundless Bio, Inc.",
  "url": "https://orbyd.app/dossiers/BOLD/",
  "json_url": "https://orbyd.app/dossiers/BOLD.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Still a merger-arb wrapper rather than an oncology stock: the object is a planned $44–48M pre-close cash dividend plus a 3.69% stub in the AATD base-editing NewCo. The 2026-08-07 10-Q re-documented it ($72.6M cash, 75% RIF), but price has run to $2.89 — 52wk high, RSI 84.6 — above the $2.41–$2.60 band where the 11.3% holder's July Form 4s printed. No S-4 on file.",
  "invalidation_trigger": "A weekly close below $2.40 loses the June–July Form 4 accumulation band and signals the spread repricing deal-break or dividend-compression risk; secondary conditions are an 8-K declaring a per-share dividend implying a total under $44M, or no S-4 on file by the end of Q3-2026.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "m-and-a-special-situations",
    "rare-disease-gene-therapy",
    "oncology-immunology"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "ecDNA oncology pipeline discontinued; BBI-940 early clinical data did not support advancing. No clinical catalyst exists in the legacy entity.",
    "On close the symbol changes to AATD and pre-merger holders retain 3.69% of the combined company. The current ticker stops representing the oncology entity.",
    "Per-share dividend, record date and ex-date were still undeclared as of 2026-08-08; the $44-48M total adjusts with net cash at closing.",
    "Close is conditioned on dual shareholder votes and SEC effectiveness of a Form S-4 that was not on file as of 2026-08-08.",
    "SERP-01 is licensed from YolTech Therapeutics, which retains Greater China rights - licensing and geopolitical tail risk on the underlying asset.",
    "A special cash distribution of the planned scale will restate dividend-adjusted price history on the ex-date; re-base any level quoted against an adjusted series."
  ],
  "body_markdown": "## Current Thesis\nSeven weeks past the 2026-06-23 announcement, the frame from the prior note holds and has now been documented in a filing. The 10-Q filed 2026-08-07 confirms the shell mechanics: $72.6M of cash and short-term investments at 2026-06-30, a ~75% workforce reduction, $10.5M of lease-termination cost, a planned pre-close cash dividend of $44–48M, and pre-merger holders retaining 3.69% of the company that emerges from the Serapha Bio reverse merger. What changed is the tape and the register. Price closed 2026-08-07 at $2.89 — the 52-week high, RSI(14) 84.6, +100.7% over three months — while the only disclosed accumulator of size, the Tang Capital complex, printed its July open-market purchases between $2.41 and $2.60 and has no Form 4 in the surveyed record after 2026-07-21. The instrument is a capped distribution plus a thin equity stub; the quote has moved up into and through the band where the informed arb buyer was filling.\n\n## Bull Case\n- 10-Q, 2026-08-07: cash and short-term investments of $72.6M at 2026-06-30 sit behind a planned $44–48M pre-close distribution. The wind-down is funded and the number is now in a periodic report rather than only a press release.\n- Schedule 13G filed 2026-06-29: Tang Capital entities disclosed 2,533,845 shares, 11.3% of 22,474,777 shares outstanding as of 2026-06-15. Tang is a specialist in exactly this object — cash-shell distributions — and kept adding after the initial block.\n- Form 4s dated 2026-07-02, 07-08, 07-13, 07-16 and 07-21 show open-market purchases at $2.41–$2.60. Continued buying three to four weeks after the announcement is a live vote on the distribution range surviving intact.\n- 2026-06-23: $230M concurrent private placement co-led by RA Capital Management and RTW Investments, $138M funded and $92M committed at close, with combined cash guided to fund operations into 2H-2029 — through Phase 2 completion and Phase 3 initiation for SERP-01.\n- The 75% headcount cut and the $10.5M lease termination booked in the 10-Q are the wind-down actually executing, which is what has to happen for cash to be freed for distribution.\n\n## Bear Case\n- 3.69% is the whole equity claim on the base-editing story. The AATD asset accrues 96.31% to Serapha equityholders and the private placement. At $2.89 the market is paying something above the disclosed distribution range for that residual, which requires the combined company to be worth materially more than its funded cash — a judgement no filing has yet supported with a pro-forma valuation.\n- The distribution is not a fixed number. The 10-Q repeats that $44–48M is subject to adjustment for net cash at closing, and the same filing books a $37.2M six-month net loss ($1.66/share) plus $10.5M of lease-termination cost. Severance from a 75% reduction and transaction fees are drawn from the same pool.\n- No per-share dividend, record date or ex-date has been declared as of 2026-08-08. The $44–48M total and the 22,474,777 shares outstanding are both on file; the company has published no per-share figure, so every valuation of this situation currently rests on an undeclared quantity.\n- No S-4 appears in the public filing record surveyed through the 2026-08-07 10-Q. The registration statement gates the shareholder votes, which gate the Q4-2026 close. Each week without it compresses the window.\n- small, but supply into the advance rather than into the close.\n- SERP-01 is licensed from YolTech Therapeutics, which retains Greater China rights. Anything that impairs a China-origin license impairs the stub, and the stub is the only part of this with open-ended upside.\n\n## Setup & Price Structure\n- 2026-08-07 close $2.89 = the 52-week high; distance from high 0.0%; three-month return +100.7%; RSI(14) 84.6. The name is at the top of its range with momentum stretched.\n- The advance from the 2026-06-23 halt-resumption print of ~$2.28 to $2.89 happened on no press releases. The company's last news release is the 2026-06-23 merger announcement; the recent-news tape for the trailing 30 days is empty.\n- $2.40–$2.60 is the observable accumulation band: every Tang Form 4 between 2026-06-29 and 2026-07-21 printed inside it, with the last purchase (4,863 shares, 2026-07-21) at $2.44. Price is now above that entire band with no disclosed follow-on buying from the 11.3% holder.\n- Ceiling structure matters more than trend here. A merger-arb wrapper converges on distribution-plus-stub; it does not trend. RSI 84.6 in a sub-$3 microcap whose upside is contractually capped is a different object from RSI 84.6 in a growth equity.\n- Life-cycle: **MATURING**. The event has been fully disclosed since 2026-06-23 and re-documented on 2026-08-07; the price is still working and making highs, but the bid is mechanical rather than headline-driven, participation is concentrated in one identifiable holder, and there is no fresh news flow. It moves toward SATURATED if price extends further above the distribution range while the S-4 and the per-share declaration stay unfiled.\n- Crowding observables, stated plainly: at the 52-week high with RSI 84.6; zero company headlines in 30 days; the largest disclosed buyer's prints stop 12–20% below the current quote; a venture holder sold into the move on 2026-07-06; float is tight with 11.3% in one complex and 22.47M shares outstanding.\n\n## Catalyst Calendar (next 30 days)\n- **Undated, any day** — 8-K or Form 425 declaring the per-share pre-close dividend with record and ex-dates. This is the single number that converts the situation from estimate to arithmetic. No date has been given.\n- **~2026-09-30 (est.)** — Form S-4 registration statement including the Boundless proxy. Not on file as of 2026-08-08; required to be effective before the shareholder votes. An S-4 landing inside Q3 keeps the Q4-2026 close credible.\n- **Rolling** — Form 4 / 13G-A amendments from the Tang complex. Renewed buying above $2.60, or any disposition, is directly observable and dated.\n- **~2026-11-12 (est.)** — Q3 2026 10-Q, the next scheduled net-cash mark before closing. Outside the 30-day window but it is the next hard date on the calendar.\n- **Q4-2026 (guided)** — merger close, ticker change to AATD. No day-level date has been published.\n\n## What Would Change Our Mind\nThe structure that has to hold is the $2.40–$2.60 accumulation band from the June–July Form 4s. Losing it says the arb is marking deal-break or dividend-compression risk rather than converging, and the 2026-06-23 announcement gap toward ~$1.40 becomes the reference. A weekly close below $2.40 is the gradeable break. Three non-price conditions would change the read independently: an 8-K declaring a per-share dividend that implies a total below $44M; the S-4 failing to appear before the end of Q3-2026, which would put the guided Q4-2026 close at risk; or a Tang 13G-A showing the 11.3% stake reduced. In the other direction, an S-4 filed with a pro-forma that supports the current implied stub value, or renewed Form 4 purchases above $2.60, would argue the market has priced this correctly rather than ahead of itself. Conviction on a fresh entry at $2.89 is low — the upside is bounded by an undeclared number and the entry sits above where the best-informed disclosed buyer stopped.\n\n## Correlation Notes\n- This has decoupled from oncology and from biotech beta. The ecDNA program was discontinued on 2026-06-23, so XBI moves transmit only through the general risk appetite for microcap deal arb, not through pipeline sentiment.\n- The stub's fair value marks against in-vivo AATD editing comparables — Beam, Wave, Arrowhead — because the residual 3.69% is a claim on the same clinical thesis (SERPINA1 E342K / PiZZ correction). Readouts or de-ratings in that cohort should move the residual, though at 3.69% the transmission is heavily damped.\n- The dominant correlation is to the Tang Capital complex's own filings.\n- A special distribution of the planned scale restates dividend-adjusted historical price series on the ex-date. Any level quoted against an adjusted series — including the ones in this note — needs re-basing once the ex-date is set.",
  "first_seen": "2026-06-26",
  "last_analyzed": "2026-08-08T14:25:56+00:00",
  "last_synthesized": "2026-08-08",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}